Which is better EGFR-TKI followed by osimertinib: afatinib or gefitinib/erlotinib?
M Tamiya, A Tamiya, H Suzuki, K Moriizumi… - Anticancer …, 2019 - ar.iiarjournals.org
Background/Aim: Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
M Tamiya, A Tamiya, H Suzuki… - Anticancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Background/aim Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
[PDF][PDF] Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
M TAMIYA, A TAMIYA, H SUZUKI… - ANTICANCER …, 2019 - ar.iiarjournals.org
Background/Aim: Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
response against NSCLC harboring EGFR mutation; however, treatment resistance occurs …
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
M Tamiya, A Tamiya, H Suzuki, K Moriizumi… - Anticancer …, 2019 - europepmc.org
Materials and methods This multicenter retrospective study evaluated outcomes between
afatinib group and 1st-G group. We analyzed clinical data from NSCLC patients receiving …
afatinib group and 1st-G group. We analyzed clinical data from NSCLC patients receiving …